{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKI&page=6", "query": { "intervention": "TKI", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 232, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKI&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKI&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T07:30:53.693Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06140836", "title": "A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Repotrectinib", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2023-12-21", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 6, "location_summary": "Des Moines, Iowa • Boston, Massachusetts • Mineola, New York + 2 more", "locations": [ { "city": "Des Moines", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06140836" }, { "nct_id": "NCT04971226", "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 405, "start_date": "2021-10-06", "completion_date": "2031-01-18", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 13, "location_summary": "Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971226" }, { "nct_id": "NCT00550537", "title": "Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 116, "start_date": "2007-10", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 7, "location_summary": "Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550537" }, { "nct_id": "NCT04417465", "title": "First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-CLS-579", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "DRUG" }, { "name": "VEGFR TKI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2020-06-03", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 5, "location_summary": "Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417465" }, { "nct_id": "NCT01397734", "title": "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2011-09", "completion_date": "2018-08-06", "has_results": false, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397734" }, { "nct_id": "NCT02450591", "title": "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oligometastatic Lung Adenocarcinoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Local Therapies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-05-14", "completion_date": "2017-12-11", "has_results": true, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02450591" }, { "nct_id": "NCT00363649", "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "GM-K562 cell vaccine", "type": "BIOLOGICAL" }, { "name": "Interferon alfa", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2006-09", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2018-11-13", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363649" }, { "nct_id": "NCT03958565", "title": "Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Tyrosine Kinase Inhibitor", "type": "BIOLOGICAL" }, { "name": "Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]", "type": "DRUG" }, { "name": "Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 100, "start_date": "2020-04-28", "completion_date": "2028-04-28", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 2, "location_summary": "Aurora, Colorado • Lone Tree, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958565" }, { "nct_id": "NCT03093116", "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "Oral repotrectinib (TPX-0005)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 500, "start_date": "2017-03-07", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 49, "location_summary": "Duarte, California • Glendale, California • La Jolla, California + 36 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093116" }, { "nct_id": "NCT02013219", "title": "A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2014-04-03", "completion_date": "2020-02-05", "has_results": false, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-11-02T07:30:53.693Z", "location_count": 10, "location_summary": "Orange, California • New Haven, Connecticut • Orlando, Florida + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013219" } ] }